Tactics of hypoglycemic treatment in patients with pancreatogenic diabetes: a prospective study

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Pancreatogenic diabetes (PD) is secondary to diseases of the pancreas. The prevalence of PD according to some data; is up to 9–10% of all cases of DM; which is comparable in frequency to type 1 DM (DM1). The tactics for choosing glucose-lowering treatment in patients with various forms of PD have not yet been fully determined; the effectiveness and tolerability of the drug in this disease have not been sufficiently studied.

Objective. Development of criteria for the safety and effectiveness of glucose-lowering treatment in patients with PD

Methods. Initially; 133 patients who had been diagnosed with pancreatitis and PD that developed as a result were followed-up. 81 (60.9%) patients – 65 men and 16 women aged 54.7±9.3 years – completed the study. Patients were randomized (envelope method) into groups differing in the treatment regimens used. In group A (therapy with insulin drugs); 37 patients completed the study; in group B (therapy with metformin; including in combination with insulin drugs) – 44 patients. Personal and family history; the structure of the pancreas according to radiation imaging methods; biochemical parameters; and the effectiveness of therapy were assessed’ and search for prognostic criteria for the effectiveness and safety of treatment was performed.

Results. The main risk factors for PD have been identified. It was found that the use of metformin in PD as monotherapy or in combination with insulin drugs improved glycemic control; reduced insulin doses; reduced the frequency of relapses of pancreatitis and the risk of of renal dysfunction. Clinical and laboratory criteria to predict the effectiveness and safety of glucose-lowering treatment for PD have been statistically substantiated.

Conclusion. The data obtained make it possible to substantiate the feasibility of using metformin as monotherapy or in combination with insulin; and to formulate recommendations for choosing the optimal tactics of drug therapy that provides a high clinical effect with satisfactory tolerability.

Full Text

Restricted Access

About the authors

I. Yu. Nikulin

Donetsk Regional Clinical Territorial Medical Association

Email: Anastasia.kutya.1997@gmail.com
ORCID iD: 0000-0002-1792-0263
Russian Federation, Donetsk

A. E. Bagriy

M. Gorky Donetsk State Medical University

Email: Anastasia.kutya.1997@gmail.com
ORCID iD: 0000-0003-2592-0906
Russian Federation, Donetsk

E. S. Mikhailichenko

M. Gorky Donetsk State Medical University

Email: Anastasia.kutya.1997@gmail.com
ORCID iD: 0000-0001-8625-1406
Russian Federation, Donetsk

Anastasia E. Kutya

M. Gorky Donetsk State Medical University

Author for correspondence.
Email: Anastasia.kutya.1997@gmail.com
ORCID iD: 0009-0009-3700-9299

Teaching Assistant at the Department of Internal Medicine № 2

Russian Federation, Donetsk

Ya. A. Sovpel

M. Gorky Donetsk State Medical University

Email: Anastasia.kutya.1997@gmail.com
ORCID iD: 0000-0002-6574-4225
Russian Federation, Donetsk

References

  1. Petrov M.S. Post-pancreatitis diabetes mellitus: prime time for secondary disease. Eur J Endocrinol. 2021;184(4):137–49. doi: 10.1530/EJE-20-0468.
  2. American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl. 1):S17–38.
  3. Andersen D.K.; Korc M.; Petersen G.M.; et al. Diabetes; pancreatogenic diabetes and pancreatic cancer. Diab. 2017;66:1103–10. doi: 10.2337/db16-1477.
  4. Тарасова Ж.С.; Бордин Д.С.; Килейников Д.В. и др. Панкреатогенный сахарный диабет: взгляд эндокринолога и гастроэнтеролога. Эффективная фармакотерапия. 2020;16(15):92–100 [Tarasova Zh.S.; Bordin D.S.; Kileynikov D.V.; et al. Pancreatogenic diabetes mellitus: the view of an endocrinologist and gastroenterologist. Effect Pharmacother. 2020;16(15):92–100. (In Russ.)]. doi: 10.33978/2307-3586-2020-16-15-92-100.
  5. Bharmal S.H.; Cho J.; Ko J.; et al. Glucose variability during the early course of acute pancreatitis predicts two-year probability of new-onset diabetes: A prospective longitudinal cohort study. United Eur. Gastroenterol. J. 2022;10(2):179–89. doi: 10.1002/ueg2.12190.
  6. American Diabetes Association Professional Practice Committee. 6. Glycemic targets: Standards of Medical Care in Diabetes-2022. Diab Care. 2022;45(Suppl. 1):S83–96.
  7. Bhattamisra S.K.; Siang T.C.; Rong C.Y.; et al. Type-3c Diabetes Mellitus; Diabetes of Exocrine Pancreas – An Update. Curr Diab Rev. 2019;5(5):382–94. doi: 10.2174/157339981566619011514570.
  8. Игнатенко Г.А.; Багрий А.Э.; Оприщенко А.А. и др. Сахарный диабет: руководство для врачей. Донецк; 2022. 640 с. [Ignatenko G.A.; Bagri A.E.; Oprishchenko A.A.; et al. Diabetes mellitus: a guide for doctors. Donetsk; 2022. 640 p. (In Russ.)].
  9. Lohr J.M.; Dominguez-Munoz E.; Rosendahl J.; et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United Eur Gastroenterol J. 2017;5(2);153–99. doi: 10.1177/2050640616684695.
  10. Дедов И.И.; Шестакова М.В.; Майоров А.Ю. и др. Сахарный диабет 2 типа у взрослых. Клинические Рекомендации. Сахарный диабет. 2020;23(2):4–102. [Dedov I.I.; Shestakova M.V.; Mayorov A.Yu.; et al. Type 2 diabetes mellitus in adults. Clinical Recommendations. Diab Mellit. 2020;23(2):4–102. (In Russ.)]. doi: 10.14341/DM12507.
  11. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes2022. Diab Care. 2022; 45(Suppl. 1):S125–43.
  12. Song A.; Zhang C.; Meng X. Mechanism and application of metformin in kidney diseases: An update. Biomed Pharmacother. 2021;138. doi: 10.1016/j.biopha.2021. 111454.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bionika Media